Sinopharm (02096.HK): XenpeyXin (Concentrated solution of idarafenib mesylate for injection) included in the 2026 edition of the National Essential Drug List.

Zhtng Cijng APP news, Sinopharm Group (02096.HK) announced that on July 9, 2026, the Group's independently developed innovative drug Xianbixin (edaravone injection concentrate) has been officially included in the "National List of Essential Medicines (2026 Edition)" for the treatment of acute ischemic stroke (AIS). According to the relevant management regulations of essential medicines, public medical institutions at all levels nationwide must equip and prioritize the use of drugs listed in the directory as required. This selection is beneficial for Xianbixin to break through the limitations of original tertiary hospitals, accelerate penetration into county-level and grassroots medical markets, expand terminal prescription scenarios, and enhance drug accessibility by leveraging existing medical insurance qualifications, further consolidating the Group's competitive advantage in the field of acute stroke treatment.